Close

Delcath Systems, Inc. (DCTH) Reports Q2 Loss of $0.52/Share

August 6, 2014 5:10 PM EDT
Get Alerts DCTH Hot Sheet
Price: $5.09 --0%

Financial Fact:
Net loss: -1.01M

Today's EPS Names:
SHIM, KOD, HEWA, More
Join SI Premium – FREE

Delcath Systems, Inc. (NASDAQ: DCTH) reported Q2 EPS of ($0.52), versus ($0.91) reported last year. Revenue for the quarter came in at $251 thousand, versus $0 reported last year.

"We continue to see steady clinical adoption of CHEMOSAT in Europe," commented Jennifer K. Simpson, Interim Co-President & Co-CEO. "As of July 31st of this year, a total of 50 treatments, of which 22 were retreatments, were performed at leading European cancer centers. This compares with 22 treatments and six retreatments during the first seven months of 2013. We believe the growth in performed treatments reflects expanded European clinical experience with CHEMOSAT. Our company-sponsored clinical program for HCC is also moving forward as the first site in Germany is now active and identifying appropriate patients for enrollment. In addition to this first site, Johan Wolfgang Goethe University Hospital in Frankfurt, we expect to add additional German sites, as well as sites in the UK and US during the remainder of 2014. Our goal is to have interim data from the company sponsored Phase 2 studies in the first half of 2015. We are pleased that two leading centers in Europe have opened their investigator initiated trials and believe that data from these trials will support our European efforts and contribute to our clinical program."

For earnings history and earnings-related data on Delcath Systems, Inc. (DCTH) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Management Comments

Related Entities

Earnings